Solabia Group, a global supplier of natural and biotech-based ingredients for cosmetics, nutrition, pharmaceutical, health and other markets, recently announced a partnership with Astorg, which has acquired a majority stake in the company from TA Associates. TA will reportedly remain a significant investor, continuing its support for Solabia’s growth ambitions.
Financials and Solabia's Biotech Focus
To support the transaction, Astorg secured approximately €600 million in financing from Goldman Sachs and Arcmont, according to market sources, as reported by PitchBook.
Founded in 1972 and headquartered in Paris, Solabia develops high-performance natural actives using biotechnologies such as:
- fermentation,
- enzymatic synthesis,
- green chemistry and
- plant extraction.
The company operates 11 manufacturing sites and eight R&D labs worldwide.
With consistent double-digit growth over the past five years and a reported EBITDA of approx. €65 million, Solabia is positioned for continued expansion, especially in the U.S. and Asia. Astorg’s investment will help accelerate product innovation and inorganic growth through M&A.
Collaborating for Continued Growth
"We are excited to welcome Astorg as a strategic partner and to continue our successful collaboration with TA," said Jean-Baptiste Dellon, CEO of Solabia. "Astorg brings deep sector expertise, a strong track record of value creation, and an entrepreneurial mindset that aligns with Solabia’s ambitions."
Astorg Partners Nicolas Marien and Paul Arhanchiague added: "With strong biotech capabilities and presence in high-growth markets, Solabia exemplifies the kind of global leader Astorg is proud to back.
Patrick Sader, managing director at TA Associates — which has supported Solabia since 2018 — added, "Solabia has transformed into a vertically integrated life sciences platform with significant growth. ... We’re thrilled to remain part of this journey alongside Astorg."
The deal is expected to close in the coming months, pending customary regulatory approvals.
